Chemours posts $381 million Q2 net loss on $257 million New Jersey settlement charge
Chemours reported second quarter 2025 net sales of $1.6 billion, up 4% from a year earlier, but swung to a net loss of $381 million, or $2.54 per diluted share, from net income of $60 million a year earlier. The company said the loss was driven mainly by litigation charges tied to its New Jersey PFAS settlement, while adjusted net income rose to $87 million, or $0.58 per share.
Key points
- Net sales were $1.6 billion, up 4% from $1,554 million in Q2 2024
- Net loss attributable to Chemours was $381 million, or $2.54 per diluted share, versus net income of $60 million, or $0.39, in Q2 2024
- Adjusted net income was $87 million, or $0.58 per diluted share, versus $58 million, or $0.38, a year earlier
- Full-year 2025 Adjusted EBITDA is expected to be $775 million to $825 million, and Q3 2025 Adjusted EBITDA $175 million to $195 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.